Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas
Status:
Withdrawn
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
GMX1777 is a water-soluble, intravenously-administered prodrug of GMX1778. GMX1777 is rapidly
converted to GMX1778 in vivo. GMX1778 has potent anti-tumor activity against a variety of
cell lines and models from different tumor origins.